[
  {
    "ts": null,
    "headline": "Denmark’s fat jab champion is slimming down the whole economy",
    "summary": "Novo Nordisk, Denmark’s fat jab pharmaceutical giant, reached an unwelcome milestone last week.",
    "url": "https://finnhub.io/api/news?id=a8f9cb5945d50c1aff726f58aec7e37241a17bf6039568b607dd6f4ce5ea56fd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772276400,
      "headline": "Denmark’s fat jab champion is slimming down the whole economy",
      "id": 139262771,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo Nordisk, Denmark’s fat jab pharmaceutical giant, reached an unwelcome milestone last week.",
      "url": "https://finnhub.io/api/news?id=a8f9cb5945d50c1aff726f58aec7e37241a17bf6039568b607dd6f4ce5ea56fd"
    }
  },
  {
    "ts": null,
    "headline": "BeOne Medicines: Guidance Weighs But Multiple Catalysts In 2026",
    "summary": "BeOne Medicines: Guidance Weighs But Multiple Catalysts In 2026",
    "url": "https://finnhub.io/api/news?id=982f70aa7054c1390255081874aca98bb42b772f7dd2b937de2f36028b5b4575",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772270100,
      "headline": "BeOne Medicines: Guidance Weighs But Multiple Catalysts In 2026",
      "id": 139263483,
      "image": "",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=982f70aa7054c1390255081874aca98bb42b772f7dd2b937de2f36028b5b4575"
    }
  },
  {
    "ts": null,
    "headline": "Benzinga Bulls And Bears: Rocket Lab, Kosmos Energy, Novo Nordisk — And Nvidia Fails To Boost Markets",
    "summary": "Benzinga examined the prospects for many investors&#39; favorite stocks over the last week — here&#39;s a look at some of our top stories.",
    "url": "https://finnhub.io/api/news?id=0f5108b1fbe971ee201989eca2205900d9c84aa56c5bd9037a3f7ccdf0472d38",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772264530,
      "headline": "Benzinga Bulls And Bears: Rocket Lab, Kosmos Energy, Novo Nordisk — And Nvidia Fails To Boost Markets",
      "id": 139262429,
      "image": "https://cdn.benzinga.com/files/images/story/2026/02/28/Bulls-and-Bears-1.jpeg?width=2048&height=1536",
      "related": "LLY",
      "source": "Benzinga",
      "summary": "Benzinga examined the prospects for many investors&#39; favorite stocks over the last week — here&#39;s a look at some of our top stories.",
      "url": "https://finnhub.io/api/news?id=0f5108b1fbe971ee201989eca2205900d9c84aa56c5bd9037a3f7ccdf0472d38"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly’s Oral GLP‑1 Win And Olumiant Update Reshape Growth Story",
    "summary": "Eli Lilly (NYSE:LLY) reported Phase 3 data showing its oral GLP-1 candidate, orforglipron, produced greater blood sugar and weight reduction in adults with type 2 diabetes than Novo Nordisk’s oral semaglutide. The company has submitted regulatory filings for orforglipron in more than 40 countries, including for obesity, with potential US approval cited for Q2 2026. Lilly and Incyte received a positive opinion from the EMA’s CHMP for Olumiant to treat adolescents with severe alopecia areata...",
    "url": "https://finnhub.io/api/news?id=1088809657de513eec64a9ad57ba14be23d5f891209b4177837de6ab95813c01",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772237939,
      "headline": "Eli Lilly’s Oral GLP‑1 Win And Olumiant Update Reshape Growth Story",
      "id": 139258808,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly (NYSE:LLY) reported Phase 3 data showing its oral GLP-1 candidate, orforglipron, produced greater blood sugar and weight reduction in adults with type 2 diabetes than Novo Nordisk’s oral semaglutide. The company has submitted regulatory filings for orforglipron in more than 40 countries, including for obesity, with potential US approval cited for Q2 2026. Lilly and Incyte received a positive opinion from the EMA’s CHMP for Olumiant to treat adolescents with severe alopecia areata...",
      "url": "https://finnhub.io/api/news?id=1088809657de513eec64a9ad57ba14be23d5f891209b4177837de6ab95813c01"
    }
  }
]